Show simple item record

Authordc.contributor.authorChevet, Eric 
Authordc.contributor.authorHetz Flores, Claudio 
Authordc.contributor.authorSamali, Afshin 
Admission datedc.date.accessioned2015-10-27T14:15:35Z
Available datedc.date.available2015-10-27T14:15:35Z
Publication datedc.date.issued2015
Cita de ítemdc.identifier.citationCancer Discovery; 5(6); 1–12en_US
Identifierdc.identifier.otherDOI: 10.1158/2159-8290.CD-14-1490
Identifierdc.identifier.urihttps://repositorio.uchile.cl/handle/2250/134684
General notedc.descriptionArtículo de publicación ISIen_US
Abstractdc.description.abstractStress induced by the accumulation of unfolded proteins in the endoplasmic reticulum (ER) is observed in many human diseases, including cancers. Cellular adaptation to ER stress is mediated by the unfolded protein response (UPR), which aims at restoring ER homeostasis. The UPR has emerged as a major pathway in remodeling cancer gene expression, thereby either preventing cell transformation or providing an advantage to transformed cells. UPR sensors are highly regulated by the formation of dynamic protein scaffolds, leading to integrated reprogramming of the cells. Herein, we describe the regulatory mechanisms underlying UPR signaling upon cell intrinsic or extrinsic challenges, and how they engage cell transformation programs and/or provide advantages to cancer cells, leading to enhanced aggressiveness or chemoresistance. We discuss the emerging crosstalk between the UPR and related metabolic processes to ensure maintenance of protein homeostasis and its impact on cell transformation and tumor growth. Significance: ER stress signaling is dysregulated in many forms of cancer and contributes to tumor growth as a survival factor, in addition to modulating other disease-associated processes, including cell migration, cell transformation, and angiogenesis. Evidence for targeting the ER stress signaling pathway as an anticancer strategy is compelling, and novel agents that selectively inhibit the UPR have demonstrated preliminary evidence of preclinical efficacy with an acceptable safety profile.en_US
Patrocinadordc.description.sponsorshipInstitut National du Cancer (INCa) Ligue Nationale Contre le Cancer (Comites des Landes) ECOS-CONICYT C13S02 FONDECYT 1140549 Millennium Institute P09-015-F Ring Initiative ACT1109 Michael J. Fox Foundation for Parkinson's Research COPEC-UC Foundation FONDEF D11I1007 Frick Foundation Irish Cancer Society CRS11CLE Breast Cancer Campaign 2010NOVPR13 Belgian grants-Interuniversity Attraction Poles IAP 7/32 CONICYT-USA2013-0003en_US
Lenguagedc.language.isoenen_US
Publisherdc.publisherAmer Assoc Cancer Researchen_US
Type of licensedc.rightsAtribución-NoComercial-SinDerivadas 3.0 Chile*
Link to Licensedc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/cl/*
Keywordsdc.subjectUnfolded-Protein Responseen_US
Keywordsdc.subjectQuality-Control Proteinsen_US
Keywordsdc.subjectXbp-1 Messenger-Rnaen_US
Keywordsdc.subjectEr-Stressen_US
Keywordsdc.subjectTranscription Factoren_US
Keywordsdc.subjectHepatocellular-Carcinomaen_US
Keywordsdc.subjectInduced Apoptosisen_US
Keywordsdc.subjectTumor-Growthen_US
Keywordsdc.subjectTransmembrane Proteinen_US
Keywordsdc.subjectKinase-Activityen_US
Títulodc.titleEndoplasmic Reticulum Stress–Activated Cell Reprogramming in Oncogenesisen_US
Document typedc.typeArtículo de revista


Files in this item

Icon

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 Chile
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 Chile